Prana Biotechnology (PRAN)

[interestingtome]

Prana fundamentals

As posted by kadaicher on ymb

Remember a development biotech has no earnings, so the fundamentals are different from a company with a product on the market.
1. Potential growth - If PBT2 makes it to market in HD then potential growth is 8000%
2. Time to market - 3 years
4. Cash on hand $30m +/-
5. Proven ability to raise more development funds from last trials.
6. Scientific talent on board. The planets most successful movement disorder trials doctor has joined the board to direct the movement disorder programs HD, PD. There are significant readings and trends from Reach2HD to design the trial around.
7. Depth in pipeline. Good with the HD,PD drug ready for final phase3 trials in HD and AD. PD drug PBT434 ready for the clinic, the cancer MPAC 519 into toxicology studies and a library of 2000 more MPACs.
8. Progress. Currently upgrading PBT2 toxicology data prior to Phase3 for FDA approval.
9. Have non clinical study results been independently replicated, Yes for AD by the Max Planck Institute in Germany and for the PD drug, by Leeds University in the UK in three different models.
10.Patent protection secure.
11.Orphan drug status for lead program.
12. Neuroprotection properties of the platform emerged on top of an unbiased 200,000 compound screening for neuroprotection against AD, HD & PD.